"Swedish Competition Authority Closes Investigation into Lupin's Pricing of Orphan Drug NaMuscla"

"Advokatfirman Delphi represented Lupin Europe GmbH and Lupin Atlantis Holdings SA in an investigation by the Swedish Competition Authority regarding allegations of overpricing an orphan drug, NaMuscla, initiated in May 2024. On October 15, 2025, the authority closed the investigation without determining if Lupin held a dominant market position. The investigation acknowledged Lupin's significant investments in repurposing NaMuscla for treating a rare disease, and a price/cost analysis led to the conclusion that the pricing was justified."

**Law Firms and Parties Involved:** Advokatfirman Delphi advised Lupin Europe GmbH and Lupin Atlantis Holdings SA (“Lupin”) in a recent investigation conducted by the Swedish Competition Authority. **Transaction Overview:** The investigation, initiated in May 2024, focused on allegations of abuse of a dominant position concerning the pricing of NaMuscla, an orphan drug for the treatment of the ultra-rare disease non-dystrophic myotonia. On 15 October 2025, the Swedish Competition Authority closed the investigation without determining whether Lupin held a dominant position. The investigation confirmed that Lupin had made significant investments to repurpose the drug, and a price/cost analysis led to the conclusion that the pricing was not excessive. **Legal Team:** The case was handled by a team led by Elisabeth Eklund and Karin Roberts, with contributions from Johan Persson Ed. The team included competition economists from RBB, led by Petter Berg and Niklas Strand, along with Bastian Haberer, Tilda Lidman, and Nanna Daugaard. The press release does not specify the seniority or practice areas of the lawyers involved.

"Swedish Competition Authority Closes Investigation into Lupin's Pricing of Orphan Drug NaMuscla"

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads